HK1207117A1 - Methods of treating diabetes and or promoting survival of pancreatic islets after transplantation - Google Patents

Methods of treating diabetes and or promoting survival of pancreatic islets after transplantation

Info

Publication number
HK1207117A1
HK1207117A1 HK15107742.9A HK15107742A HK1207117A1 HK 1207117 A1 HK1207117 A1 HK 1207117A1 HK 15107742 A HK15107742 A HK 15107742A HK 1207117 A1 HK1207117 A1 HK 1207117A1
Authority
HK
Hong Kong
Prior art keywords
transplantation
methods
treating diabetes
pancreatic islets
promoting survival
Prior art date
Application number
HK15107742.9A
Other languages
English (en)
Chinese (zh)
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of HK1207117A1 publication Critical patent/HK1207117A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15107742.9A 2012-04-18 2015-08-11 Methods of treating diabetes and or promoting survival of pancreatic islets after transplantation HK1207117A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
HK1207117A1 true HK1207117A1 (en) 2016-01-22

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107742.9A HK1207117A1 (en) 2012-04-18 2015-08-11 Methods of treating diabetes and or promoting survival of pancreatic islets after transplantation

Country Status (15)

Country Link
US (3) US10081809B2 (xx)
EP (1) EP2839004B1 (xx)
JP (2) JP6348484B2 (xx)
KR (1) KR20150003824A (xx)
CN (2) CN107252492A (xx)
AU (1) AU2013249191B2 (xx)
CA (1) CA2870547A1 (xx)
DK (1) DK2839004T3 (xx)
ES (1) ES2732252T3 (xx)
HK (1) HK1207117A1 (xx)
IN (1) IN2014DN08158A (xx)
MX (1) MX370149B (xx)
NZ (1) NZ630914A (xx)
RU (1) RU2667960C2 (xx)
WO (1) WO2013158868A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
HUE032368T2 (en) 2008-11-13 2017-09-28 Nogra Pharma Ltd Antisense preparations and methods for their preparation and application
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2940115B1 (en) * 2014-04-30 2018-10-17 The Procter and Gamble Company Cleaning composition
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
EP3790975A4 (en) * 2018-05-08 2022-10-26 University of Miami MATERIALS AND METHODS FOR DELIVERING THERAPEUTIC NUCLEIC ACIDS TO TISSUE
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
DK2336317T3 (da) * 2003-06-13 2019-12-16 Alnylam Europe Ag Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
PL1799269T3 (pl) 2004-09-28 2017-01-31 Quark Pharmaceuticals, Inc. Oligorybonukleotydy i sposoby ich zastosowania do leczenia łysienia, ostrej niewydolności nerek i innych chorób
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
US8022046B2 (en) * 2008-04-18 2011-09-20 Baxter International, Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
HUE032368T2 (en) 2008-11-13 2017-09-28 Nogra Pharma Ltd Antisense preparations and methods for their preparation and application
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2673209T3 (es) 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US20210207143A1 (en) 2016-02-24 2021-07-08 Nogra Pharma Limited Methods of Treating Celiac Disease Using SMAD7 Inhibition
EP3562943A1 (en) 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
MX370149B (es) 2019-12-03
CN104487574A (zh) 2015-04-01
IN2014DN08158A (xx) 2015-05-01
AU2013249191B2 (en) 2019-01-03
RU2667960C2 (ru) 2018-09-25
NZ630914A (en) 2017-01-27
CN104487574B (zh) 2017-07-07
RU2014146170A (ru) 2016-06-10
KR20150003824A (ko) 2015-01-09
DK2839004T3 (da) 2019-07-01
US10443056B2 (en) 2019-10-15
JP6348484B2 (ja) 2018-06-27
EP2839004B1 (en) 2019-06-12
EP2839004A1 (en) 2015-02-25
JP2018131468A (ja) 2018-08-23
AU2013249191A1 (en) 2014-10-09
JP2015514778A (ja) 2015-05-21
WO2013158868A1 (en) 2013-10-24
US20200239884A1 (en) 2020-07-30
US20190136237A1 (en) 2019-05-09
CA2870547A1 (en) 2013-10-24
CN107252492A (zh) 2017-10-17
US20150315573A1 (en) 2015-11-05
MX2014012650A (es) 2015-04-08
ES2732252T3 (es) 2019-11-21
US10081809B2 (en) 2018-09-25

Similar Documents

Publication Publication Date Title
HK1207117A1 (en) Methods of treating diabetes and or promoting survival of pancreatic islets after transplantation
EP2675459A4 (en) COMPOUNDS AND METHODS FOR TREATING DIABETES
SG10201609579QA (en) Fiber-Reinforced Hydrogel Composites And Methods Of Forming Fiber-Reinforced Hydrogel Composites
IL238943B (en) Controlled release preparations and methods of using them
EP2890391A4 (en) METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA
EP2640461A4 (en) SYSTEMS AND METHOD FOR TREATING THE DRY EYE
EP2831291A4 (en) MANIPULATED LEATHER AND METHOD FOR THE PRODUCTION THEREOF
EP2748787A4 (en) METHOD AND SYSTEM FOR SHARING DEVICE ACTIVITIES
EP2825635A4 (en) SYSTEMS AND SUBSTANCES FOR THE CRYOPRESERVATION OF VIABLE CELLS
HK1200348A1 (en) Methods and materials for treatment of pompes disease
GB201217296D0 (en) Method of treatment and/or prevention
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
EP2919983A4 (en) ARTICLES WITH FIBER-REINFORCED POLYMERS AND METHOD OF USE THEREOF
ZA201301936B (en) Methods and compositions for treatment of diabetes and dyslipidemia
HK1214355A1 (zh) 用於治療和/或限制糖尿病發展的方法
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
HK1259004A1 (zh) 治療糖尿病的組合物和方法
ZA201504167B (en) Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates
ZA201404689B (en) Umbilical splint and method of use
HK1208783A1 (en) Composition and method for management of diabetes or pre-diabetes
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP2935317A4 (en) GHRH AGONISTS FOR GRAFT AND THE FUNCTION OF ISLAND CELLS AND THE TREATMENT OF DIABETES
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
GB201102364D0 (en) Lock means and method of use thereof